Peripheral Artery Disease Clinical Trial
Official title:
Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)
NCT number | NCT02542267 |
Other study ID # | ISR 14-04 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2015 |
Est. completion date | July 2021 |
Verified date | October 2023 |
Source | W.L.Gore & Associates |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of the ISR 14-04 study is to evaluate post-market safety and effectiveness of GORE® VIABAHN® Endoprosthesis for treatment of In-Stent Restenosis of the Superficial Femoral Artery.
Status | Completed |
Enrollment | 108 |
Est. completion date | July 2021 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient has a previously implanted (> 30 days) non-covered stent(s) located in the SFA - Patient has life-style limiting claudication, resting leg pain or minor tissue loss (Rutherford Category 2 - 5) - Patient demonstrates an Ankle Brachial Index (ABI) <=0.9. If ABI >0.9 or not measurable, patient is eligible for study if Toe Brachial Index is <=0.5 - Patient has >=50% in-stent restenosis and / or an occlusion in a previously implanted (>30 days) non-covered stent(s) located in the superficial femoral artery defined as beginning at least 1cm below the origin of the profunda femoris artery and ending at least 1cm above the intercondylar notch. - Patient has a maximum total lesion length of 270mm, consisting of in-stent and adjacent occlusive disease - Patient has a reference vessel diameter between 4.0 and 6.5mm - Patient has at least one patent infrapopliteal runoff vessel (<50% stenosis) not requiring reintervention - Note: Additional Inclusion Criteria may apply Exclusion Criteria: - Patient has a known allergy to stent graft components (nickel-titanium or expanded-polytetrafluoroethylene) - Patient has a known intolerance to anticoagulation or antiplatelet therapy - Patient has known coagulation disorder, including hypercoagulability. - Patient has major distal amputation (above the transmetatarsal) - Patient has any previous surgery in the target vessel - Patient has had previous target vessel in-stent restenosis treated by relining with another stent - Patient has untreated flow-limiting aortoiliac stenotic disease - Note: Additional Exclusion Criteria may apply |
Country | Name | City | State |
---|---|---|---|
Germany | Klinikum Rosenheim | Rosenheim | |
Italy | Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia | Reggio Emilia | |
Sweden | Skånes Universitetssjukhus | Malmo | |
United States | Charleston Area Medical Center | Charleston | West Virginia |
United States | Texas Health Research - Presbyterian Heart and Vascular | Dallas | Texas |
United States | St. Vincent's Consultants in Cardiovascular Disease | Erie | Pennsylvania |
United States | Sanford Health | Fargo | North Dakota |
United States | Greenville Hospital System | Greenville | South Carolina |
United States | Kaiser Foundation Hospital | Honolulu | Hawaii |
United States | Cardiovascular Institute of the South | Houma | Louisiana |
United States | University of Iowa Hospitals and Clinics | Iowa City | Iowa |
United States | Mount Sinai Medical Center | Miami | Florida |
United States | New York Presbyterian Hospital/Weill Cornell Medical Center | New York | New York |
United States | New York University Langone Medical Center | New York | New York |
United States | Midwest Aortic and Vascular Institute (MAVI) | North Kansas City | Missouri |
United States | Texas Health Research - Presbyterian Hospital of Plano | Plano | Texas |
United States | Providence Heart Clinic | Portland | Oregon |
United States | The Miriam Hospital | Providence | Rhode Island |
United States | North Carolina Heart and Vascular | Raleigh | North Carolina |
United States | Rockford CardioVascular Associates | Rockford | Illinois |
United States | Covenant Medical Center, Inc. | Saginaw | Michigan |
United States | Swedish Medical Center - Heart and Vascular Research | Seattle | Washington |
United States | Munson Medical Center | Traverse City | Michigan |
Lead Sponsor | Collaborator |
---|---|
W.L.Gore & Associates |
United States, Germany, Italy, Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Effectiveness | Primary Effectiveness is Primary Patency defined as patent blood flow through the study device, which requires either a Peak Systolic Velocity Ratio measurement = 2.5 or patent flow indicated by the Core Lab, and without repeat intervention measured at 12 months and assessed by Kaplan-Meier analysis. | 12 Months | |
Primary | Number of Subjects Free From Procedure and Device-Related Serious Adverse Events Within 30 Days of Index Procedure | Primary Safety is defined as freedom from procedure and device-related serious adverse events within 30 days of index procedure | 30 Days | |
Secondary | Number of Subjects With Acute Procedural Success | Acute Procedural Success is defined as successful delivery of the study device and complete coverage of the target lesion without a procedure or device-related Serious Adverse Event prior to hospital discharge. | During hospitalization, approximately 1-2 days | |
Secondary | Primary Patency at 30 Days and 12, 24, and 36 Months | Primary patency is defined as patent blood flow through the study device, which requires either a PSVR measurement = 2.5 or patent flow indicated by the Core Lab, without repeat intervention. | 30 days and 12, 24, and 36 months | |
Secondary | Primary Assisted Patency at 30 Days and 12, 24, and 36 Months | Primary assisted patency is defined as blood flow through the study device regardless of repeat interventions to maintain patency prior to occlusion. | 30 days and 12, 24, and 36 months | |
Secondary | Secondary Patency at 30 Days and 12, 24, and 36 Months | Secondary patency is defined as blood flow through the study device regardless of repeat interventions to restore patency after occlusion. | 30 days and 12, 24, and 36 months | |
Secondary | Freedom From Target Lesion Revascularization at 30 Days and 12, 24, and 36 Months | Target Lesion Revascularization is defined as a repeat intervention within the study device and 5 mm proximal or distal to the edge of the study device to maintain or re-establish patency. | 30 days and 12, 24, and 36 months | |
Secondary | Freedom From Major Amputation at 30 Days and 12, 24, and 36 Months | Major Amputation is defined as removal of the study limb above the metatarsals, resulting from a vascular event. | 30 days and 12, 24, and 36 months | |
Secondary | Change in Ankle Brachial Index at 30 Days | The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. | Pre-procedure and 30 Days | |
Secondary | Change in Ankle Brachial Index at 1 Year | The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. | Pre-procedure and 1 Year | |
Secondary | Change in Ankle Brachial Index at 2 Years | The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. | Pre-procedure and 2 Years | |
Secondary | Change in Ankle Brachial Index at 3 Years | The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. | Pre-procedure and 3 Years | |
Secondary | Change in Rutherford Category at 30 Days | The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. | Pre-procedure and 30 Days | |
Secondary | Change in Rutherford Category at 1 Year | The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. | Pre-procedure and 1 Year | |
Secondary | Change in Rutherford Category at 2 Years | The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. | Pre-procedure and 2 Years | |
Secondary | Change in Rutherford Category at 3 Years | The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. | Pre-procedure and 3 Years | |
Secondary | Stent Fracture at 12, 24, and 36 Months | Device stent fractures that are clearly distinguishable from previously implanted stents will be assessed by the study core lab through x-ray images. | 12, 24, and 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05712395 -
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
|
N/A | |
Active, not recruiting |
NCT04534257 -
Prospective Registry to Investigate the Safety and Efficacy of the Treatment With the Selution Sirolimus Drug Coated Balloon in TASC C and D Atheroma-occlusive Infra-Inguinal Disease in Patients With Chronic Limb Threatening Ischemia From Singapore
|
N/A | |
Recruiting |
NCT04511234 -
Sirolimus Coated Balloon Versus Standard Balloon for SFA and Popliteal Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Completed |
NCT02554266 -
Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries
|
||
Completed |
NCT03921905 -
Peripheral Artery Disease in Patients With Stable Coronary Artery Disease in General Practice: Prevalence, Management and Clinical Outcomes.
|
||
Not yet recruiting |
NCT06369350 -
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
|
Early Phase 1 | |
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Completed |
NCT02522884 -
Tack Optimized Balloon Angioplasty Study of the Tack Endovascular Systemâ„¢ in Femoropoliteal Arteries
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Completed |
NCT02563535 -
Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia
|
Phase 4 | |
Completed |
NCT02145065 -
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
|
N/A | |
Completed |
NCT02228564 -
BARD® Study of LIFESTREAMâ„¢ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease
|
N/A | |
Completed |
NCT02262949 -
A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System
|
N/A | |
Completed |
NCT01743872 -
Optical Imaging Measurement of Intravascular Solution Efficacy Trial
|
N/A | |
Recruiting |
NCT01424020 -
Walking Estimated Limitation Calculated by History - Study 2
|
Phase 4 | |
Active, not recruiting |
NCT01597453 -
NOR-SYS: The Norwegian Stroke in the Young Study
|
N/A | |
Withdrawn |
NCT00569686 -
Lovaza Therapy of Peripheral Arterial Disease
|
N/A |